Search

Seventeen cases of granular cell tumor (GCT) of the breast are reviewed. The demographics and clinical features are reviewed and the radiologic and pathologic features as well as the immunohistochemistry are discussed. To our knowledge, our series of 17 breast GCT cases represent the largest series published to date. [ABSTRACT FROM AUTHOR]

Expected postoperative enhancement on breast MRI can appear similar to enhancement seen in recurrent or residual malignancy. Our aim was to assess the time course and patterns of enhancement at the surgical site, thereby helping to distinguish between benign and malignant postoperative enhancement. In 200 MRI scans performed in 153 patients after breast conservation treatment, 43 after surgical excision of atypia, and 4 patients after benign excisional biopsy were categorized by postoperative time interval. We defined 4 patterns of morphologic enhancement on MRI: cavity wall/seroma (Pattern I); thin linear (Pattern II); mass (Pattern III); and fat necrosis (Pattern IV). Of 200 MRI scans, 66 (33%) demonstrated enhancement at the surgical site. Enhancement typically decreased through the postoperative follow-up period. Enhancement was observed in 41% (28/68) of cases beyond the 18-month interval but was uncommon after 5 years. Pattern III enhancement was the morphologic pattern seen most commonly with malignancy (5/19 cases, 26%). When associated with delayed washout kinetics, it was even more strongly predictive of malignancy (4/5 cases, 80%). In patients with a history of excisional biopsy and no prior radiation treatment, the percentage of MRI scans showing enhancement was significantly lower than (21% vs 49% with P-value .0027) in patients who had undergone radiation. Enhancement at the surgical site occurred in one-third of cases up to 5 years after surgery, particularly in patients who underwent both radiation and surgery. Mass enhancement, particularly in conjunction with delayed washout kinetics, is most predictive of malignancy and should prompt biopsy or re-excision., (© 2018 Wiley Periodicals, Inc.)

After benign concordant magnetic resonance imaging (MRI)-guided breast biopsy, initial follow-up MRI at 6 months is often recommended for confirmation. This study was undertaken to determine the proper management of stable lesions on initial follow-up MRI and whether such follow-up can be safely deferred to 12 months. Retrospective review of 240 MRI-guided biopsies identified 156 benign concordant lesions. 85 eligible cases received follow-up MRI and constitute the study population. On initial follow-up MRI, 72 of 85 lesions appeared adequately sampled, 12 were stable and underwent further MRI follow-up, and 1 was benign on subsequent surgery. No cancers were diagnosed at the biopsy sites on either 6- or 12-month follow-up MRI. Among the 12 stable lesions, four were masses and eight were nonmass enhancements. One of the stable masses enlarged on 24-month follow-up MRI and proved malignant. All stable nonmass lesions were benign on long-term follow-up. After benign concordant MRI-guided breast biopsy, a stable mass has a 25% probability of malignancy in our series. Re-biopsy of such masses should be strongly considered. Stable nonmass lesions may be followed with subsequent MRI without rebiopsy. Deferral of initial follow-up MRI to 12 months may be acceptable., (© 2015 Wiley Periodicals, Inc.)